Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18170600 | 0.87 | KMT2A (0.44) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL18170461 | 0.85 | MEN1 (0.52) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL18170896 | 0.83 | CASP3 (0.41) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL18170549 | 0.83 | KDR (0.53) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL18171017 | 0.82 | MEN1 (0.48) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL18170467 | 0.82 | MEN1 (0.48) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL18170515 | 0.80 | MLYCD (0.47) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL18170590 | 0.80 | CYP11B1 (0.57) | NPC1RAB9ACASP3KDRLMNA | |
| SCHEMBL18170783 | 0.79 | KCNMA1 (0.51) | MEN1KMT2ACASP3KDRNPSR1 | |
| SCHEMBL18170925 | 0.78 | CASP3 (0.47) | NPC1RAB9AMEN1KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | claimed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | claimed |
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TNIK, TNK1, NFKBIA | NPC1 2005/4885RAB9A 2823/4885MEN1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.